On the other side of the pond another prestigious Institute of Public Health is collaborating.
WEST HAVEN, Conn., Jul 08, 2013 (BUSINESS WIRE) -- NanoViricides, Inc. NNVC -1.54% (the "Company") said it has signed a "confidential disclosure agreement" with Public Health England, the British government's equivalent of the U.S. Centers for Disease Control. The agreement will allow the scientists at Public Health England to develop a specific proposal for the testing of different nanoviricides, such as FluCide(R), against viruses of "mutual interest" to both organizations. More specifically, the first two viruses of mutual interest are H7N9, the influenza virus now circulating in China as well as the latest version of the coronavirus, now circulating in the Middle East. It is now referred to as the MERS virus. This virus is similar to the SARS virus that infected 8000 people and killed approximately 800 people 10 years ago. Both H7N9 and the MERS CoV (coronavirus) have extremely high case fatality rates. Testing of nanoviricides antiviral drug candidates will be performed in a BSL3/4 facility at PHE. BSL3/4 facilities are designed to contain and enable the safe handling of organisms that can pose a significant threat to health.
"...All the Lego pieces are already in the box, thanks to the genius of Dr. Anil Diwan, Dr. Eugene Seymour and a few others. If the NanoViricides team can cure dengue — and I believe they can — they can quickly go on to cure other orphan tropical diseases. West Nile, Rift Valley, Lassa, Ebola, Marburg, Bunya and Chikungunya are only the obvious targets. Believe me, the people running NanoViricides know about the priority voucher program and understand its implications. Once they have scaled up, I believe they could produce a new orphan tropical disease cure every two weeks..." ~ Patrick Cox
It's interesting how NNVC is moving to prepare the new FluCide (R) for MERS in order to proceed with tox studies. Like "Lego" pieces coming together. Thank you.
